Plexium is an emerging biotechnology company focused on the identification of E3 ligase modulating small molecules to treat cancer and neurodegenerative diseases. The company's screening platform, named DELPhe for DNA-Encoded Library (DEL) phenotypic (Phe) screening, utilizes droplet and microwell confinement to miniaturize cell-based assays that yield high content readouts at very low cost and very high throughput. Plexium is gathering a comprehensive catalog of chemical and biological interactions of E3 ligases and aims to lead this field by discovering and developing new therapeutics internally and with partners.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/22/19 | $28,000,000 | Series A |
CRV DCVC  M Ventures NeoTribe Ventures The Column Group | undisclosed |
| 01/21/21 | $35,000,000 | Series A Extension |
DCVC Lux Capital Pivotal bioVenture Partners The Column Group | undisclosed |
